We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Chất ức chế BTK
MedXY News
EnglishTag

Chất ức chế BTK

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

IL-16 Production as a Mechanism of Resistance to BTK Inhibitors and R-CHOP in B-Cell Lymphomas: Mechanistic Insights and Therapeutic Implications
Clinical UpdatesIL-16Chất ức chế BTK

IL-16 Production as a Mechanism of Resistance to BTK Inhibitors and R-CHOP in B-Cell Lymphomas: Mechanistic Insights and Therapeutic Implications

By MedXY|Sep 12, 2026

This review synthesizes evidence on IL-16-driven resistance to BTK inhibitors and chemoimmunotherapy in B-cell lymphomas, highlighting the IL-16/CD9/PI3K axis as a targetable epigenetically regulated survival pathway overcoming drug resista

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia
Hematology-OncologyChất ức chế BTK
CLL

Personalised T-Cell Activation Shows Promise in Overcoming Minimal Residual Disease in Chronic Lymphocytic Leukaemia

By MedXY|Feb 19, 2026

A Phase 1 study demonstrates that iTAC-XS15-CLL01, a personalised multipeptide T-cell activator, induces robust immune responses in 95% of CLL patients on BTK inhibitors, offering a potential path to sustainable cancer control and eradicati

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial
NeurologyChất ức chế BTKfenebrutinib

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial

By MedXY|Dec 23, 2025

The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 w

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities